Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders

NCT02983188 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT02983188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02983188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders
Lead sponsor
The University of Hong Kong
Phase
Phase 2/3
Overall status
Completed
Start date
April 25, 2018
Completion date
January 4, 2021
Enrollment
113 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic syndrome x, schizophrenia, schizophrenia spectrum and other psychotic disorders